<DOC>
	<DOCNO>NCT01757392</DOCNO>
	<brief_summary>The primary objective study determine safety Candin® ( Candida albicans Skin Test Antigen ) 0.3 ml dose level 6 monthly injection treat common wart ( Verruca vulgaris ) .</brief_summary>
	<brief_title>Candin Safety &amp; Efficacy Study Treatment Warts</brief_title>
	<detailed_description>The primary objective study determine safety Candin® ( Candida albicans Skin Test Antigen ) either 0.3 mL dose level 6 monthly injection ( maximal , cumulative dose 1.9 mL , include delayed-type hypersensitivity ( DTH ) test ) treat common wart ( Verruca vulgaris ) . A secondary objective understand relative effectiveness 0.3 dose level treat common wart , inject inject well type wart inject allow determination appropriate dose level use future dose-ranging efficacy trial .</detailed_description>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Warts</mesh_term>
	<criteria>Must least 3 10 common wart locate palm digit Positive DTH response Candin® require No previous medical treatment wart OTC No immunocompromising medical condition medicine allow No preexist inflammatory condition treatment site allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Treatment</keyword>
	<keyword>common wart lesion</keyword>
	<keyword>( verruca vulgaris )</keyword>
</DOC>